Neuphoria Therapeutics Inc. (NEUP) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Neuphoria Therapeutics Inc. on December 18, 2025. The filing addresses a regulatory matter concerning the company's continued listing on The Nasdaq Stock Market, LLC.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance rather than financial performance.
Material Changes and Events
- Listing Deficiency: On July 18, 2025, the company received a deficiency notification from Nasdaq for failing to hold a qualified annual meeting of stockholders within twelve months of the fiscal year ended June 30, 2024 (Listing Rule 5620(a)).
- Resolution: The company held its 2025 annual general shareholder meeting on December 12, 2025, consistent with its historical practice of holding meetings in November or December.
- Compliance Restored: On December 18, 2025, Nasdaq Staff confirmed the company has regained compliance with the Listing Rule, and the matter is now closed.
Outlook, Risks, and Management Commentary
Management includes standard forward-looking statements cautioning that actual results may differ due to risks and uncertainties. Specific risks highlighted include the ability to maintain the listing of securities on Nasdaq. The company disclaims any obligation to update these forward-looking statements.
Key Facts for Investor Verification
- Verify the company's current stock listing status on Nasdaq to confirm no new deficiencies have arisen.
- Review the company's most recent 10-K or 10-Q filings for actual financial performance data, as this 8-K contains no financial metrics.
- Confirm the date and outcome of future annual shareholder meetings to ensure continued compliance with Nasdaq Listing Rule 5620(a).